Archives
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br Methods br Results br Discussion TA
2021-10-16

Methods Results Discussion TA-TMA is a severe complication for patients after HSCT. The pathogenesis of TA-TMA is unclear. Complement activation and endothelial cell injury may be involved in the pathogenesis of TA-TMA. Our previous investigations had demonstrated that plasma levels of C5b-
-
HPgV coinfection has been associated with reduced liver dise
2021-10-16

HPgV coinfection has been associated with reduced liver disease in HPgV/HCV/HIV triply infected patients (Barbosa Ade et al., 2009, Berzsenyi et al., 2007, Berzsenyi et al., 2009, Berzsenyi et al., 2011). It is possible that HCV NS3 protease inhibitors could inhibit HPgV replication diminishing its
-
In contrast to sGC stimulators sGC activators promote enzyma
2021-10-16

In contrast to sGC stimulators, sGC activators promote enzymatic activity of sGC containing oxidized heme iron (Fe3+) or missing the heme group. A-350619 is one of the oldest activators of sGC to be discovered. A-350619 increased sGC activation in a non-additive manner with respect to YC-1, leading
-
br Materials and methods br Results br Discussion Directly
2021-10-16

Materials and methods Results Discussion Directly modulating specific target proteins and signaling pathways with small-molecule drugs or agonistic Spermine NONOate is widely used for cancer metastasis therapies [[39], [40], [41]]. ANXA7 acts as a metastasis suppressor in prostate cancer. H
-
Also the decrease in adipocyte cAMP
2021-10-16

Also, the decrease in adipocyte cAMP levels seen after an acute glucose challenge in wild-type mice was strongly reduced in mice lacking GPR81, indicating that the activation of PDE3B alone was not sufficient to mediate the effect of insulin on cAMP levels and lipolytic activity. The fact that insul
-
In Locusta migratoria a worldwide agricultural pest
2021-10-16

In Locusta migratoria, a worldwide agricultural pest, we previously identified 51 CPRs containing eight endocuticle structural glycoproteins, which are homologs of SgAbd-1, SgAbd-2, SgAbd-3, SgAbd-4, SgAbd-5, SgAbd-6, SgAbd-8, and SgAbd-9 in the adult desert locust, Schistocerca gregaria [17,26]. Al
-
Given and a module N we put
2021-10-16

Given and a -module N, we put The right hand side makes sense because we regard g as an KH 7 australia of and meanwhile . It is also a skew group ring, identified with via the following equation It follows that becomes a -module, with Analogous to the situation of group representations, the underlyi
-
Cy5 NHS ester (non-sulfonated) Increasing evidence has shown
2021-10-16

Increasing evidence has shown that blockade of glutamate uptake leads to aberrant behavioral consequences. For example, intracerebroventricular (i.c.v) injection or microinjection of the GLT-1 inhibitor, dihydrokainic Cy5 NHS ester (non-sulfonated) (DHK), into the prefrontal cortex induces anhedoni
-
GSK2126458 br Introduction The alternative splicing
2021-10-16

Introduction The alternative splicing of pre-mRNA is essential for generating multiple matured mRNAs from a single gene by selectively removing introns. Neural GSK2126458 show many examples of regulated alternative splicing events, which produce structural changes in proteins important for the d
-
While TUNEL staining is traditionally thought to
2021-10-16

While TUNEL staining is traditionally thought to be an apoptosis marker, studies have shown that TUNEL can stain necrotic RK-33 receptor [19], [20], [21]. Furthermore, DNA degradation has also been observed in necrotic cells [22]. TUNEL staining alone is therefore insufficient to distinguish apopto
-
br Pannexins which form channels connecting cells with the e
2021-10-15

Pannexins, which form channels connecting phenylephrine hydrochloride with the extracellular environment, have also been studied in the setting of NASH. When open these channels participate in inflammatory processes. A decrease in lobular inflammation and oxidative stress was observed in mice wit
-
The PK and the tissue distribution profiles of
2021-10-15

The PK and the tissue distribution profiles of 15k, 15j, 14d and 2 (Table 8) in male ICR mice were assessed. 15k, 15j, 14d all exhibited prolonged half-lives and improved plasma exposure. 15k achieved the highest concentration (15.45 μg/mL) in plasma among four compounds. The observation that 15j (S
-
Syt itself does not catalyze lipid mixing and membrane
2021-10-15

Syt1 itself does not catalyze lipid mixing and membrane fusion. Rather, the pairing of vesicular and target membrane SNAREs into complexes serves to pull bilayers together to drive fusion; Ca•syt1 accelerates these fusion reactions so that they occur on rapid timescales in a manner that is precisely
-
Over the years a number of studies have reported results
2021-10-15

Over the years, a number of studies have reported results concerning the behavior of the two endothelin receptor subtypes, ETA and ETB, that do not fit the classical model of two G protein-coupled receptors acting independently of one another. For example, in the rat anterior pituitary gland, both E
-
The only approved H R antagonist inverse agonist is BF
2021-10-15

The only approved H3R antagonist/inverse agonist is BF2.649 (1- 3-[3-(4-chlorophenyl)propoxy]propyl piperidine), developed by Bioprojet and known as pitolisant (Wakix®). It was approved by the European Medicines Agency in March 2016 and marketed in the European Union to be used in narcolepsy with or
16164 records 575/1078 page Previous Next First page 上5页 571572573574575 下5页 Last page